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We are well aware of Hoehler's position on the efficacy of DL-HMTBA relative to DLM and the tenacity with which he holds it despite overwhelming evidence to the contrary. At its foundation, his position is based on a misunderstanding and misapplication of linear and exponential slope ratio bioavailability methods (Kratzer and Littell, 2006) . These methods were developed to estimate the relative bioavailability of the same nutrient in different matrixes (e.g., Lys in wheat, corn, and soybean meal) with a standard of known and preferably high bioavailability (such as Lys-HCl; Ammerman et al, 1995) . Thus, once the nutrient is available for absorption, all other aspects of metabolism are identical. When comparing the bioavailability of DLM and DL-HMTBA, the assumptions required for validity of these bioavailability methods cannot be accepted (Kratzer and Littell, 2006) . This is because DL-HMTBA and DLM are different molecules: DL-HMTBA is not Met; it is a precursor of Met. As such, DL-HMTBA is metabolized substantially differently than DLM once presented to the animal for absorption (Dibner, 2003; Lobely, 2005) . Consequently, DL-HMTBA does not function as a dilution of DLM; rather, the 2 compounds demonstrate different forms of dose responses. For a complete discussion of these differences and the appropriate methodology to use in comparing the sources, the reader is referred to Kratzer and Littel (2006) , Vázquez-Añ ó n et al. González-Esquerra et al. (2007) .
It is true that our paper compared DL-HMTBA from Mintrex with DL-HMTBA from Alimet feed supplement and did not include a DLM treatment (Yi et al., 2007) . Nevertheless, the body of published evidence demonstrates that DL-HMTBA from any commercially available source is fully available as a source of Met activity.
